Health Topics — Stress & Anxiety
CBG and the HPA Axis
CBG may interact with the hormonal pathway that drives the stress response — the biology behind that possibility, what research has confirmed, and what remains an open question.
The hypothalamic-pituitary-adrenal axis is the body's central stress coordination system. It governs the sequence of events that follows perceived threat — from the initial neurological detection to the release of cortisol and the feedback processes that are supposed to bring the system back to rest.
CBG interacts with this system through several documented mechanisms. What the research has established, what it has not, and why the distinction matters — that is what this article covers.
The HPA Axis: A Brief Map
Understanding where CBG enters the stress response requires a clear picture of how the response is organized. The HPA axis is a three-stage hormonal cascade that connects the brain's stress detection circuitry to the body's physiological response.
The HPA Axis Stress Cascade
Hypothalamus detects threat
Releases corticotropin-releasing hormone (CRH). The amygdala — involved in emotional threat assessment — feeds into this signal.
Pituitary responds to CRH
Releases adrenocorticotropic hormone (ACTH) into the bloodstream.
Adrenal glands release cortisol
Cortisol mobilizes energy, sharpens attention, and prepares the body for response. It is the primary measurable output of HPA activation.
Negative feedback loop closes the response
Cortisol suppresses further CRH and ACTH release. The hypothalamus and hippocampus detect elevated cortisol and signal the system to stand down. In a well-functioning system, this returns the body to baseline.
Endocannabinoid signaling — including CBG-relevant mechanisms — acts across multiple stages
CB1 receptors in the hypothalamus, amygdala, and hippocampus modulate CRH release, threat assessment, and negative feedback sensitivity. CBG's alpha-2 adrenoceptor and GABAergic mechanisms are relevant to the arousal and inhibitory dimensions of this cascade.
How CBG Intersects With the HPA Axis
Tier 2 — Preclinical and Mechanistic
CBG does not interact with the HPA axis through a single mechanism. Its pharmacological profile includes several distinct receptor interactions, each relevant to a different stage or dimension of the stress response.
Mechanism 1
Alpha-2 Adrenoceptor Agonism
CBG is a highly potent alpha-2 adrenoceptor agonist (Cascio et al., 2010). Alpha-2 receptors regulate norepinephrine release — the primary driver of acute stress arousal. Agonism at these receptors reduces norepinephrine signaling, dampening the arousal component of the acute stress response.
Mechanism 2
GABA Reuptake Inhibition
CBG inhibits GABA reuptake, increasing GABAergic tone. GABA is the brain's primary inhibitory neurotransmitter and the main system through which the nervous system moderates excitatory stress responses. Increased GABA availability supports inhibitory control over HPA axis activation.
Mechanism 3
CB1 Receptor Activity
CBG acts as a partial agonist at CB1 receptors, which are expressed in the hypothalamus, amygdala, and hippocampus — regions directly involved in HPA axis initiation, threat assessment, and negative feedback. Endocannabinoid signaling at these sites modulates CRH release and cortisol feedback sensitivity.
Mechanism 4
5-HT1A Antagonism
CBG acts as a 5-HT1A receptor antagonist. 5-HT1A receptors are involved in serotonergic stress modulation and are the target of several pharmaceutical anxiolytics. CBG's activity here is antagonistic rather than agonistic — the functional significance of this in the stress context is still under investigation.
These mechanisms do not operate in isolation. They interact with each other and with the broader signaling context of the stress response. Alpha-2 adrenoceptor agonism and GABA reuptake inhibition converge on the arousal and inhibition dimensions of the acute stress response. CB1 activity is relevant across multiple stages of the HPA cascade. The picture is not one mechanism with one effect — it is a pharmacological profile that touches the stress response system at several points simultaneously.
What preclinical means here
All four mechanisms above are documented in preclinical research — receptor pharmacology studies, animal behavioral models, and in vitro studies. They establish that CBG interacts with stress-relevant biological systems in documented ways. They do not establish that CBG reduces cortisol in humans, modulates HPA axis activity in clinical stress populations, or produces any specific clinical outcome.
Mechanism is the rationale for human investigation. It is not a substitute for it.
What the Human Trial Data Shows
Tier 1 — Human Trial Evidence
The Cuttler et al. (2024) randomized controlled trial is the only published human trial of CBG's acute effects. Thirty-four healthy adults received a single 20mg oral dose of CBG or placebo in a double-blind crossover design. The trial found statistically significant reductions in self-reported anxiety and stress compared to placebo at 20, 45, and 60 minutes post-dose.
What the Cuttler trial did not measure is the cortisol question directly. Stress was assessed through validated self-report instruments — measures of the subjective experience of stress — not through cortisol assay, ACTH measurement, or any direct biological marker of HPA axis activity. The trial confirms that participants reported less stress after CBG than after placebo, at this dose, at these time points, in this healthy adult population. It does not confirm that CBG modulated cortisol levels or altered HPA axis function in measurable biological terms.
This is not a criticism of the trial's design — self-report measures of stress are valid and meaningful research outcomes. It is a specification of what the trial established and what it left open. The HPA axis mechanism for CBG's observed stress effects remains plausible, preclinically supported, and not yet directly tested in humans.
The Cortisol Question
Cortisol is the most commonly discussed marker of HPA axis activity and the measure most people associate with biological stress. Elevated cortisol — particularly chronic elevation — is associated with sleep disruption, immune suppression, metabolic effects, and impaired cognitive function. The question of whether CBG affects cortisol directly is therefore one of the more clinically significant open questions in CBG stress research.
The preclinical literature provides grounds for asking it. CBG's CB1 activity at hypothalamic receptor sites is relevant to CRH release, the first step in cortisol production. Its GABAergic and alpha-2 mechanisms are relevant to the neural arousal that drives HPA activation. Animal models have documented stress-related behavioral effects of CBG consistent with HPA modulation. None of this constitutes evidence that human cortisol levels are measurably affected by CBG. It constitutes a mechanistic case for designing a study that tests that question directly.
That study has not yet been published. Until it is, the cortisol question is held at Tier 2 — a well-founded open question, not an established finding.
Particular relevance to women's health
Cortisol reactivity varies with estrogen levels and across the menstrual cycle. The HPA axis is modulated differently by female sex hormones — a dimension this article cannot resolve because the human research does not yet exist. The Women's Health pillar covers the cortisol-estrogen-endocannabinoid intersection in detail. For readers following this question specifically, those articles carry the fuller picture.
Chronic Stress and Endocannabinoid Tone
One further dimension of the CBG-HPA axis relationship deserves attention: the difference between acute stress response and chronic stress. The Cuttler trial examined acute effects — a single dose, measured over one hour. Most of the human experience of problematic stress is chronic rather than acute: sustained activation, impaired recovery, the cumulative physiological cost of a system that does not fully return to baseline.
Preclinical research has suggested that chronic stress depletes endocannabinoid tone over time — reducing anandamide availability, downregulating CB1 receptor expression, and impairing the feedback mechanisms that terminate cortisol release after a stressor passes. Whether CBG can support endocannabinoid tone under conditions of chronic stress — and whether that support has measurable effects on HPA axis function — is an important open question that single acute-dose trials cannot answer.
The research trajectory points toward these questions. The answers require repeated-dose trials, longer observation windows, and direct biological measurement of HPA markers. That work is ahead of where the published literature currently stands.
CBG's pharmacological profile — alpha-2 adrenoceptor agonism, GABA reuptake inhibition, CB1 activity across HPA axis circuitry — represents a convergence of mechanisms relevant to how the stress response is initiated, sustained, and resolved. The mechanistic case for CBG's involvement in HPA axis regulation is preclinically established and biologically coherent.
The human evidence — one well-designed acute trial in healthy adults showing statistically significant subjective stress reduction — is a meaningful start. The cortisol question, the chronic stress question, and the repeated-dose question are all open. They are the right next questions, and the research that answers them will determine how much of the mechanistic story translates to clinical reality.
This archive will reflect those answers when they exist.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.